南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

真皮脂肪组织重塑缓解抗EGFR治疗皮肤毒性的机制研究

Remodeling of dermal adipose tissue alleviates cutaneous toxicity induced by anti-EGFR therapy

Leying Chen, Qing You, Min Liu, Shuaihu Li, Zhaoyu Wu, Jiajun Hu, Yurui Ma, Liangyong Xia, Ying Zhou, Nan Xu, Shiyi Zhang

Journal:eLife

IF:8.71

DOI:10.7554/eLife.72443

PMID:35324426

Published:2022-03-24

research field:肿瘤学生物化学

Abstract

Anti-epidermal growth factor receptor (EGFR) therapy–associated cutaneous toxicity is a syndrome characterized by papulopustular rash, local inflammation, folliculitis, and microbial infection, resulting in a decrease in quality of life and dose interruption. However, no effective clinical intervention is available for this adverse effect. Here, we report the atrophy of dermal white adipose tissue (dWAT), a highly plastic adipose tissue with various skin-specific functions, correlates with rash occurrence and exacerbation in a murine model of EGFR inhibitor-induced rash. The reduction in dWAT is due to the inhibition of adipogenic differentiation by defects in peroxisome proliferator-activated receptor γ (PPARγ) signaling, and increased lipolysis by the induced expression of the lipolytic cytokine IL6. The activation of PPARγ by rosiglitazone maintains adipogenic differentiation and represses the transcription of IL6, eventually improving skin functions and ameliorating the severity of rash without altering the antitumor effects. Thus, activation of PPARγ represents a promising approach to ameliorate cutaneous toxicity in patients with cancer who receive anti-EGFR therapy.

本文使用的Yeasen产品

购物车
客服
转染试用